Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers.


Clinical Trial Description

M1 prime is a segment of IgE found only in the membrane form of IgE and not on soluble IgE found in serum. Membrane IgE (and M1prime) is expressed on IgE-switched B cells, IgE-memory B cels, and IgE-plasmablasts. Depletion of IgE-switched B cells and plasmablasts will reduce IgE-producing cells and serum IgE, and may be a target for treatment of allergic asthma. A humanized antibody targeting M1 prime is being developed by Genentech, Inc., as a potential therapeutic for asthma.

Currently, the efficacy of MEMP1972A is being assessed in an allergen challenge study in mild asthmatics (MOP4843g). Extensive biomarker samples have been incorporated in that study to characterize the mechanism of action (MOA) as well as the kinetics of the MOA of MEMP1972A, which are poorly understood at this time. Furthermore, samples for the B cell enriched peripheral blood flow cytometry and bone marrow aspirates to evaluate the kinetics and MOA of MEMP1972a are collected only 24 hr after allergen challenge due to visit and sample volume limitations. It is known that maximal B cell responses are expected ~7 days after allergen stimulation. Therefore, the purpose of this research study will be to characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers. ;


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01420003
Study type Interventional
Source Hamilton Health Sciences Corporation
Contact
Status Completed
Phase N/A
Start date November 2011
Completion date July 2014

See also
  Status Clinical Trial Phase
Completed NCT01448954 - A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma Phase 2
Withdrawn NCT01049178 - Randomized Controlled Trial of Silymarin in Asthma Phase 2/Phase 3
Terminated NCT00644514 - Genetics of Asthma - Bronchoscopy Studies Phase 1
Completed NCT00861211 - Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects Phase 2
Completed NCT00784459 - The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics Phase 2
Terminated NCT00671593 - Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge Phase 1
Completed NCT05098600 - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Completed NCT02758548 - Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects Phase 2
Completed NCT01179256 - Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma N/A
Completed NCT01545245 - Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants N/A
Completed NCT03603522 - Probiotics and Capsaicin Evoked Coughs N/A
Completed NCT04728711 - A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC) Phase 2
Recruiting NCT03928431 - Restoration of Microbiota in Neonates N/A
Completed NCT02327234 - Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma N/A
Completed NCT01890161 - A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma Phase 2
Completed NCT03665701 - Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites N/A
Completed NCT04397081 - Atopic Diseases & Human Papilloma Virus